Your Cart Is Empty!
Biosimilars: US Payer Perspectives pulls back the curtain on the US biologics market and provides detailed and actionable insights from 12 expert US payers from a range of different organisations, including Pharmacy Benefit Managers, Managed Care Organisations and Integrated Delivery Networks. In addition, receive an Advisory Highlights management summary which covers key findings from the report.
Spending on biologics is set to reach $100 billion in the US over the next couple of years, and biosimilars are seen as a potential safety valve that can relieve some of the pressure on a healthcare system that is creaking under the weight of declining resources, increasing demands and expensive new product launches.
Caught in the middle of this are the payers, an important stakeholder group whose voice and insight is critically important in understanding the opportunities, challenges and critical success factors that companies operating in the US biosimilars market need to know and understand.
With the US lagging behind many other developed nations in terms of making biosimilars available to its healthcare system, its perhaps ironic that recent events have put opportunities and challenges within the US biosimilars market firmly on the pharma industrys radar. Five 351(k) submissions have now been made to the FDA, and a biosimilar has been approved - filgrastim-sndz from Sandoz, called Zarxio. Companies are partnering and acquiring assets that will allow them to maximise the opportunities, and investors in biosimilar companies have been cheered by share price surges and forecasts from some leading investment banks claiming that biosimilars in the US are on the cusp of greatness.
Biosimilars: US Payer Perspectives provides a much needed tonic to perhaps the overly optimistic sentiment that has seeped into the discussions about the US biosimilars opportunity. Critically it provides unique payer insights on some of the critical market shaping issues that are dominating discussions, including pricing, substitution, switching, indication extrapolation, naming and originator company defensive tactics.
The US market holds many opportunities for biosimilar developers, but in order to leverage these opportunities and maximise chances of success, biosimilar developers and originator companies must read this report to understand what payers really think, and how they will act in response to cheaper biologics becoming available.
- Understand what payers are focused on in their efforts to cut the costs of biologic therapies on their plans, and how they would prefer to make savings in order to limit disruption to their members
- Identify what payers perceive as the biggest drivers and resistors to biosimilar usage in the US, and how health plan design and payer activities could shape the biosimilars market in the US
- Learn what payers believe are the critical success factors in the US biosimilars market, including pricing strategies, educational efforts, physician engagement and provision of clinical data
- Benchmark potential pricing, market share and source of business across five key classes of product, including modern insulin, filgrastim, EPO-alfa, oncology mAbs and non-oncology mAbs
Get Answers to Critical Questions
- What current strategies for cost-containment in biologic therapy are being used by payers in the US?
- How do payers expect to manage inclusion of biosimilars on to their formularies, and what critical pieces of information will they need to see before making any decisions?
- From the payers perspective, what are the current levels of awareness, familiarity and acceptance of biosimilars at the payer and physician level, both personally and generally across each stakeholder group?
- What do payers see as the key drivers and resistors of biosimilar usage in the US?
- Do payers agree with the current US Food and Drug Administration (FDA) requirements for biosimilars, and what are their expectations for future regulatory refinements?
- What do US payers see as the most important reimbursement challenges for biosimilars, including insights on rebating and payment models?
- How do payers expect pricing dynamics within the US biosimilars market to evolve, and what are their expectations in relation to the pricing of originator biologics in response to biosimilar competition?
- What are the views of US payers in relation to the key market shaping issues of switching, automatic substitution, extrapolation of indications and biosimilar naming?
- What do US payers see as the critical success factors for the US biosimilars market, both from a biosimilar and originator biologic manufacturer perspective?
FirstWord interviewed 12 payers and also sought the opinions of a range of commercial, regulatory, legal and clinical experts to deliver contemporary, actionable and robust insight on the US biosimilars market:
- Pharmacy Director, Health Plan Division; Pharmacy Benefit Manager
- Chief Medical Officer & Chair of P&T Committee; Regional Health Plan
- VP, Pharmacy Services; Managed Care Organisation
- Executive VP, Rx Analytics; Pharmacy Benefit Manager
- Chief Medical Officer; Integrated Delivery Network
- VP, Formulary Management; Medicaid Plan
- National Senior Medical Director; Managed Care Organisation
- Pharmacy Director; Managed Care Organisation
- Medical Director; Managed Care Organisation
- Chief Pharmacy Officer; Pharmacy Benefit Manager
- Pharmacy Director; Regional Health Plan
- Pharmacy Director; Managed Care Organisation
About FirstWord Reports
FirstWord is an innovative industry intelligence leader serving over 240,000 Pharma and MedTech professionals worldwide. FirstWord offers a range of products and services designed to help your company gain a competitive edge by making key business decisions with speed and confidence.
- FirstWord Reports deliver timely, need-to-know intelligence about your products, your competitors and your markets. FirstWord Reports provide expert views and intelligence on the challenges facing pharma today in these topic areas: Biosimilars, Market Access, Medical Affairs, Sales & Marketing, Technology, Therapy Areas.
- FirstWord Pharma PLUS is a personalised and comprehensive intelligence service delivering up-to-the-minute pharma news, insight, analysis and expert views of importance to your companys success.
Learn more at www.firstwordgroup.com.
Following are different modes of Licenses.
a. Single User License:
This license allows only one person to use the report. This person can use the report on any computer and may take print outs of the report but must take care of not sharing the report (or any information contained therein) with any other individual or people. Unless you purchase a Site License or a Global Site License, a Single User License must be purchased for every single person that wishes to use the report within the same enterprise.
b. Single Site License:
This license allows unlimited users to use the report within one company location, e.g. a regional office. These users can use the report on any computer and may take print outs of the report but must take care of not sharing the report (or any information contained therein) with any other individual or people.
c. Global Site License:
A Global Site License (or Enterprise wide Site License or Global License) is a license granted to original purchaser, who can share a report with other employees and authorized Users of the same organization.
1. How do you deliver the reports?
The delivery of reports is depends on format & mode of license of report(s). Following are different kinds of formats of report(s) and their delivery options :
a. Electronic Format – Through email from Publisher
Report will be sent to your username email address in PDF, Excel, PowerPoint or any other electronic / softcopy format by publisher.
Delivery Time: 12 to 48 hours [depending on time difference or occurrences of national holidays]
b. Hard Copy or Printed Format or CD-Rom – Through Mail or Courier from Publisher
Report will be sent through mail / courier delivery to your shipping address by publisher.
Delivery Time: Less than, few weeks [depending on time difference or occurrences of national holidays]
2. How can I make payment for publications I purchase?
You could be able to make the payment, in following ways:
a. Online Secure Payment through Credit Card Payment : We accept Visa, Master, AMEX Cards & CCAvenue
b. Transfer of fund to our bank account via Bank transfer or Wire transfer
c. Payment via DD or Cheque
3. Is it safe to use my credit card on MarketinfoResearch?
Your personal information and online tranaction on Marketinfo Research is secure, private, and tamper-proof. All credit card payments are processed through secure and trusted payment gateways.